6th World Congress on Leishmaniasis
17 May
Parallel Session
Non-invasive field adapted tools (and biomarkers) for VL diagnosis and test of cure
Chair: Israel Cruz, FIND, Geneva, Switzerland
Co-chair: Anabela Cordeiro, Universidade do Porto, Porto, Portugal
| Challenges and progress toward a simple point of care diagnostic test for Visceral Leishmaniasis in East Africa Maowia Mukhtar, Institute of Endemic Diseases, University of Khartoum, Sudan |
| RDTs and diagnostic algorithms in the management of persistent fever syndrome in VL endemic areas François Chappuis, University of Geneva, Geneva, Switzerland |
| Development of prognostic serological biomarkers for visceral leishmaniasis and their relevance to disease control Michael Miles, London School of Hygiene and Tropical Medicine, London, UK |
| The diagnostic challenges and needs in the kala-azar elimination programme in South Asia Suman Rijal, DNDi, India |
VL drug discovery
Chair: Charles Mowbray, DNDi, Geneva, Switzerland
Co-chair: Mitsuyuki Shimada, Takeda, Tokyo, Japan
| The A to Z of drug discovery Kevin Read, Drug Discovery Unit, Dundee University, Dundee, UK |
| Kinetoboxes: the beginning of a beautiful friendship María Marco-Martín. GlaxoSmithKline, Madrid, Spain |
| Novel antileishmanial agents: amino-pyrazole ureas with potent in vitro and in vivo activity Paul A Glossop, Sandexis |
| Discovery and optimization of a new class of potent antileishmanial compounds and determination of their mechanism of action Frantisek Supek, Genomics Institute of the Novartis Research Foundation, San Diego, US |
Outbreak assessment & surveillance
Chair: Pierro Olliaro, WHO/TDR, Geneva
Co-chair: Suman Rijal, DNDi, India
| New estimates of leishmaniasis incidence in selected high burden countries José Antonio Ruiz Postigo, WHO, Geneva, Switzerland |
| Re-emergence and outbreaks of VL Bart Ostyn, Institute of Tropical Medicine, Antwerp, Belgium |
| Early warning systems Iván Véle, PECET-Universidad de Antioquia, Medellín, Colombia |
| Tools for rapid assessment of VL outbreaks Mercè Herrero, WHO, Geneva, Switzerland |
Oral Communications Session
Clinical and experimental therapy in CL and VL
| Pharmacokinetics of simultaneously administered antileishmanial and antiretroviral drugs in HIV/VL co-infected patients in Ethiopia Kip AE, Blesson S, Alves F, Menza P, Mengesha B, Kimutai R, Schellens JHM, Beijnen JH, Wasunna M, Hailu A, Diro E, Dorlo TPC |
Satellite Symposium
An overview of thermotherapy for the treatment of cutaneous leishmaniasis
Sponsored by Thermosurgery Technologies
Chair: Abhay Satoskar, Wexner Medical Center, Ohio State University, Columbia, USA
| Introduction and overview of thermotherapy Gina Zischke, Thermosurgery Technologies, USA |
| Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials Ivan D Valez, PECET, Medellin, Colombia |
| Longterm efficacy of radio frequency heat therapy in cutaneous leishmaniasis caused by L. tropica in India PA Bumb, SP Medical College, Bikaner, Rajasthan, India |
| Treatment of displaced populations or in conflict areas Najibullah Safi, MoPH, Afghanistan |
| The immunology of a healing response in cutaneous leishmaniasis treated with localized heat therapy Ines Elakhal Naouar & Naomi Aronson, Uniformed Services University of the Health Sciences, Bethesda, USA |
| Thermotherapy plus miltefosine for the treatment of cutanous leishmaniasis Byron Arana, DNDi, Geneva, Switzerland |
